{"meshTagsMajor":["Cell Survival","Drug Resistance, Neoplasm","Epithelial-Mesenchymal Transition"],"meshTags":["Adaptor Proteins, Signal Transducing","Adenocarcinoma","Animals","Carcinoma, Pancreatic Ductal","Cell Survival","Colonic Neoplasms","Drug Resistance, Neoplasm","Epithelial-Mesenchymal Transition","Humans","Lung Neoplasms","Pancreatic Neoplasms","Phosphoproteins","Proto-Oncogene Proteins","Proto-Oncogene Proteins p21(ras)","ras Proteins"],"meshMinor":["Adaptor Proteins, Signal Transducing","Adenocarcinoma","Animals","Carcinoma, Pancreatic Ductal","Colonic Neoplasms","Humans","Lung Neoplasms","Pancreatic Neoplasms","Phosphoproteins","Proto-Oncogene Proteins","Proto-Oncogene Proteins p21(ras)","ras Proteins"],"genes":["YAP1","Ras","YAP1","K-Ras","K-Ras"],"publicationTypes":["Comment","Journal Article"],"abstract":"It is of great therapeutic importance to understand why tumors relapse after the failure of therapies targeting oncogenes to which cancer cells are addicted. In this issue, Kapoor et al. and Shao et al. identify the transcriptional coactivator YAP1 as a central driver of compensation for the loss of K-Ras signaling in K-Ras-dependent cancers.","title":"YAP1 takes over when oncogenic K-Ras slumbers.","pubmedId":"24995973"}